Botulinum toxin type A

Generic Name
Botulinum toxin type A
Brand Names
Botox, Botox Cosmetic, Dysport, Jeuveau, Xeomin, Nuceiva
Drug Type
Biotech
Chemical Formula
-
CAS Number
93384-43-1
Unique Ingredient Identifier
0A6JH35GMQ
Background

In 2002, botulinum toxin A, also known as onabotulinumtoxinA or Botox, was the first type A botulism toxin to be introduced into the market for cosmetic use. With a wide variety of applications and favourable safety profile, Botulinum toxin A injection is a minimally invasive and promising treatment for cosmetic imperfections, muscle spasms, and other conditions. A popular use for Botox is the treatment of facial wrinkles and lines, however, there are many uses for the botulinum toxin A in the treatment of dystonia, incontinence, migraine, blepharospasm, and hyperhidrosis.

Indication

Botulinum toxin A is indicated for a variety of conditions, depending on the preparations. Cosmetically, it is used for the treatment of facial fine lines and wrinkles, specifically for upper facial rhytides, including forehead, lateral canthus, and glabellar lines.

In addition to the above indications, botulinum toxin A is used for the following conditions: treatment of adults with symptomatic overactive bladder with or without incontinence, treatment of incontinence in adult patients who are not candidates for anticholinergic therapy, treatment of Neurogenic Detrusor Overactivity (NDO) in patients over 5 years who cannot undergo anticholinergic therapy. Botulinum toxin A is indicated for the prevention of chronic migraines, for the treatment of muscle spasms, cervical dystonia, axillary hyperhidrosis, strabismus, and disorders of the 7th cranial nerve.

Off-label, botulinum toxin A is used for a variety of conditions such as temporomandibular joint (TMJ) disorders and myofascial pain, neurogenic thoracic outlet syndrome, epicondylitis, post-stroke pain, post-herpetic neuralgia, diabetic neuropathy, trigeminal neuralgia, neuropathic pain, spinal cord injury, and bladder pain.

Associated Conditions
Bladder pain, Blepharospasm, Cervical Dystonia, Chronic Migraine, Diabetic Neuropathies, Epicondylitis, Equinus deformity of foot, acquired, Facial Skin Wrinkles, Glabellar Frown Lines (GL), Lower Limb Spasticity, Myofascial Pain Syndrome, Neurogenic Detrusor Overactivity, Neurogenic Thoracic Outlet Syndrome, Overactive Bladder Syndrome (OABS), Post Stroke Pain, Postherpetic Neuralgia, Sialorrhea, Spasticity, Spinal Cord Injuries, Strabismus, TMJ Disorders, Trigeminal Neuralgia (TN), Upper Limb Spasticity, Urinary Incontinence (UI), Hypertonicity disorders of the 7th nerve, Moderate Glabellar Frown Lines (GL), Severe Glabellar Frown Lines (GL), Severe axillary hyperhidrosis
Associated Therapies
-

Dose Finding Study for a Botulinum Toxin Type A Injection to Treat Habitual Snoring

First Posted Date
2012-01-24
Last Posted Date
2013-06-19
Lead Sponsor
Merz Pharmaceuticals GmbH
Target Recruit Count
8
Registration Number
NCT01515371
Locations
🇩🇪

Merz Investigational Site #049294, Regensburg, Germany

The Biomechanical Effects of Flaccid Paralysis Induced by Botulinum Toxin a After Damage Control Laparotomy

First Posted Date
2011-12-20
Last Posted Date
2016-04-27
Lead Sponsor
Mayo Clinic
Target Recruit Count
46
Registration Number
NCT01495962
Locations
🇺🇸

Mayo Clinic in Rochester, Rochester, Minnesota, United States

🇺🇸

Regions Hosptial, St. Paul, Minnesota, United States

A Comparison Study of Oxybutynin and Botulinum Toxin for Neurogenic Detrusor Overactivity

Not Applicable
Completed
Conditions
Interventions
First Posted Date
2011-11-22
Last Posted Date
2011-11-22
Lead Sponsor
Centro de Reabilitação e Readaptação Dr. Henrique Santillo
Target Recruit Count
68
Registration Number
NCT01477736
Locations
🇧🇷

UNICAMP, Division of Urology, Campinas, Sao Paulo, Brazil

Comparison of Two Treatments for Strabismus Correction: Botulinum Toxin A Associated to Surgery and Surgery Alone

First Posted Date
2011-10-26
Last Posted Date
2011-10-26
Lead Sponsor
University of Campinas, Brazil
Target Recruit Count
23
Registration Number
NCT01460355
Locations
🇧🇷

State University of Campinas, Campinas, São Paulo, Brazil

Botulinum Toxin Injection to Treat Diffuse Esophageal Spasm

First Posted Date
2011-09-13
Last Posted Date
2011-09-13
Lead Sponsor
Universitaire Ziekenhuizen KU Leuven
Target Recruit Count
30
Registration Number
NCT01432782
Locations
🇧🇪

University Hospitals Leuven, Leuven, Vlaanderen, Belgium

Botulinum Toxin to Improve Results in Cleft Lip Repair

First Posted Date
2011-09-07
Last Posted Date
2011-09-07
Lead Sponsor
Chang Gung Memorial Hospital
Target Recruit Count
120
Registration Number
NCT01429402
Locations
🇨🇳

Chun Shin Chang, Taoyuan, Taiwan

Botulinum Toxin Injections for Thoracic Outlet Syndrome

First Posted Date
2011-07-29
Last Posted Date
2011-07-29
Lead Sponsor
University of British Columbia
Target Recruit Count
60
Registration Number
NCT01405482
Locations
🇨🇦

G F Strong Rehabilitation Centre, Vancouver, British Columbia, Canada

Special Drug Use Investigation for Botox® (Botulinum) Spasticity (BOTOX is a Registered Trademark of Allergan, Inc.)

Completed
Conditions
Interventions
First Posted Date
2011-07-11
Last Posted Date
2015-03-27
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
1038
Registration Number
NCT01390922

Botulinum Toxin Type A in Treatment of Cranial Allodynia in Patients With Headache

First Posted Date
2011-05-23
Last Posted Date
2011-05-23
Lead Sponsor
Federal University of Bahia
Target Recruit Count
40
Registration Number
NCT01357798
Locations
🇧🇷

Hospital Universitário Alcides Carneiro, Campina Grande, Paraíba, Brazil

MEDITOXIN® Versus BOTOX® in the Treatment of Post-stroke Spasticity of the Upper Limb Spasticity

Phase 3
Completed
Conditions
Interventions
First Posted Date
2011-03-14
Last Posted Date
2019-03-29
Lead Sponsor
Medy-Tox
Target Recruit Count
196
Registration Number
NCT01313767
Locations
🇰🇷

Seoul National University Hospital, Seoul, Korea, Republic of

© Copyright 2024. All Rights Reserved by MedPath